Investing Ideas
/
Mexican Pharmaceuticals & Biotech Undervalued based on future growth

Mexican Pharmaceuticals & Biotech Undervalued based on future growth

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)

1 companies

Genomma Lab Internacional. de

Market Cap: Mex$21.4b

Provides pharmaceutical and personal care products primarily in Mexico and internationally.

LAB B

Mex$21.76

2.4%

15.9%